BioTime (NASDAQ:BTX) will post its quarterly earnings results after the market closes on Thursday, August 8th. Analysts expect BioTime to post earnings of ($0.06) per share for the quarter.
BioTime (NASDAQ:BTX) last released its quarterly earnings data on Thursday, May 9th. The company reported $0.30 EPS for the quarter, topping the consensus estimate of ($0.06) by $0.36. The firm had revenue of $0.93 million for the quarter, compared to analysts’ expectations of $0.66 million.
BTX traded up $0.01 during trading on Tuesday, hitting $0.99. 3,010 shares of the stock were exchanged, compared to its average volume of 726,215. The stock has a 50 day moving average price of $1.11. BioTime has a 1 year low of $0.66 and a 1 year high of $2.81.
BioTime Company Profile
BioTime, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy.
Read More: 52-Week High/Low Prices For Stock Selection
Receive News & Ratings for BioTime Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime and related companies with MarketBeat.com's FREE daily email newsletter.